(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
0.56% $ 19.61
Live Chart Being Loaded With Signals
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 3.20M |
Średni wolumen | 2.38M |
Kapitalizacja rynkowa | 5.01B |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $0.930 ) 2024-06-04 |
Last Dividend | $0.280 ( 2023-11-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | 4.91 |
ATR14 | $0.0210 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-29 | Arjona Ferreira Juan Camilo | Buy | 108 932 | Stock Option (right to buy) |
2024-03-29 | Arjona Ferreira Juan Camilo | Buy | 26 595 | Restricted Stock Units |
2024-03-31 | Morrissey Joseph T. Jr. | Buy | 7 794 | Common Stock |
2024-03-31 | Morrissey Joseph T. Jr. | Sell | 2 328 | Common Stock |
2024-03-31 | Morrissey Joseph T. Jr. | Buy | 3 936 | Common Stock |
INSIDER POWER |
---|
64.91 |
Last 100 transactions |
Buy: 2 246 661 | Sell: 486 702 |
Wolumen Korelacja
Organon & Co. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Organon & Co. Korelacja - Waluta/Towar
Organon & Co. Finanse
Annual | 2023 |
Przychody: | $6.26B |
Zysk brutto: | $3.75B (59.84 %) |
EPS: | $4.01 |
FY | 2023 |
Przychody: | $6.26B |
Zysk brutto: | $3.75B (59.84 %) |
EPS: | $4.01 |
FY | 2022 |
Przychody: | $6.17B |
Zysk brutto: | $3.88B (62.84 %) |
EPS: | $3.61 |
FY | 2021 |
Przychody: | $6.30B |
Zysk brutto: | $3.92B (62.21 %) |
EPS: | $5.33 |
Financial Reports:
No articles found.
Organon & Co. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.280 | 2021-08-20 |
Last Dividend | $0.280 | 2023-11-10 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-14 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | $2.80 | -- |
Avg. Dividend % Per Year | 2.08% | -- |
Score | 4.57 | -- |
Div. Sustainability Score | 9.93 | |
Div.Growth Potential Score | 4.34 | |
Div. Directional Score | 7.13 | -- |
Year | Amount | Yield |
---|---|---|
2021 | $0.560 | 1.68% |
2022 | $1.120 | 3.59% |
2023 | $1.120 | 3.99% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
ZTR | Dividend Royal | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.179 | 1.500 | 6.42 | 9.63 | [0 - 0.5] |
returnOnAssetsTTM | 71.16 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.79 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0.261 | -1.000 | 7.39 | -7.39 | [0 - 1] |
currentRatioTTM | 1.649 | 0.800 | 6.76 | 5.41 | [1 - 3] |
quickRatioTTM | 0.834 | 0.800 | 9.80 | 7.84 | [0.8 - 2.5] |
cashRatioTTM | 0.226 | 1.500 | 9.86 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.733 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0.792 | 1.000 | -0.818 | -0.818 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.68 | 2.00 | 9.11 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.870 | 2.00 | 9.07 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 181.54 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.590 | 1.000 | 3.49 | 3.49 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0662 | 1.000 | -0.675 | -0.675 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 78.62 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 397.50 | 0.800 | 10.00 | 8.00 | [0.5 - 2] |
Total Score | 9.93 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 5.93 | 1.000 | 9.50 | 0 | [1 - 100] |
returnOnEquityTTM | -2.79 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.870 | 2.00 | 9.38 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 5.71 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.68 | 2.00 | 9.11 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.261 | 1.500 | 7.39 | -7.39 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.145 | 1.000 | 8.88 | 0 | [0.1 - 0.5] |
Total Score | 4.34 |
Organon & Co.
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej